empagliflozin Articles
Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz
26 March 2013
Lilly and Boehringer adjust LY2605541 deal; announce positive Ph III data for empagliflozin
8 January 2013
Highlights of American Diabetes Association meeting
11 June 2012
Showing 1-3 of 3 articles
- 1
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
